(Total Views: 540)
Posted On: 08/26/2024 12:18:58 AM
Post# of 154583
Quote:
The question is, can the original off patent drug (bevacizumab) re-apply for patent in this combination treatment with leronlimab for this MSS mCRC indication and will that new patent again protect that newly patented drug Avastin + leronlimab for another 12 years?
Avastin would be the same as the original drug so no new patent or patent protection. Avastin would have to be substantially modified and gain a new patent. Avastin as an already approved drug would not get an FDA 12 year exclusivity either.
(5)
(0)
